Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 4 April 2008. doi:10.1136/thx.2007.081877
Thorax 2008;63:578-583
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
thx.2007.081877v1
63/7/578    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cross, M D
Right arrow Articles by Douglas, N J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cross, M D
Right arrow Articles by Douglas, N J
Topic Collections
Right arrowRelevant Article

SLEEP-DISORDERED BREATHING

Continuous positive airway pressure improves vascular function in obstructive sleep apnoea/hypopnoea syndrome: a randomised controlled trial

M D Cross1, N L Mills2, M Al-Abri1, R Riha1, M Vennelle1, T W Mackay1, D E Newby2, N J Douglas1

1 Department of Sleep Medicine, University of Edinburgh, Edinburgh, UK
2 Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Correspondence to:
Dr M Cross, The University of Edinburgh, Chancellor’s Building, Edinburgh EH16 4SB, UK; melanie.cross{at}ed.ac.uk

Background: The obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is associated with hypertension and increased cardiovascular risk, particularly when accompanied by marked nocturnal hypoxaemia. The mechanisms of these associations are unclear. We hypothesised that OSAHS combined with severe nocturnal hypoxaemia causes impaired vascular function that can be reversed by continuous positive airways pressure (CPAP) therapy.

Methods: We compared vascular function in two groups of patients with OSAHS: 27 with more than 20 4% desaturations/h (desaturator group) and 19 with no 4% and less than five 3% desaturations/h (non-desaturator group). In a randomised, double blind, placebo controlled, crossover trial, the effect of 6 weeks of CPAP therapy on vascular function was determined in the desaturator group. In all studies, vascular function was assessed invasively by forearm venous occlusion plethysmography during intra-arterial infusion of endothelium dependent (acetylcholine 5–20 µg/min and substance P 2–8 pmol/min) and independent (sodium nitroprusside 2–8 µg/min) vasodilators.

Results: Compared with the non-desaturator group, patients with OSAHS and desaturations had reduced vasodilatation to all agonists (p = 0.007 for all). The apnoea/hypopnoea index and desaturation frequency were inversely related to peak vasodilatation with acetylcholine (r = –0.44, p = 0.002 and r = –0.43, p = 0.003) and sodium nitroprusside (r = –0.42, p = 0.009 and r = –0.37, p = 0.02). In comparison with placebo, CPAP therapy improved forearm blood flow to all vasodilators (p = 0.01).

Conclusions: Patients with OSAHS and frequent nocturnal desaturations have impaired endothelial dependent and endothelial independent vasodilatation that is proportional to hypoxaemia and is improved by CPAP therapy. Impaired vascular function establishes an underlying mechanism for the adverse cardiovascular consequences of OSAHS.



Relevant Article

Airwaves
Wisia Wedzicha
Thorax 2008 63: 571. [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society